Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round

Eisai and Biogen have released more data on lecanemab, another anti-Alzheimer’s drug in the partnership that spawned aducanumab. However, questions about the data remain when looking at ARIA-E events, with the typical caveat of cross-trial comparisons.